E11.3211 Insurance Policy Changes

ICD-10 E11.3211 is officially defined as "Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye." code E11.3211 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E11.3211 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Effective Jul 16, 2025Medium impact
Revakinagene Taroretcel-lwey (Encelto) (CPB 1079, reviewed 2026-10-05)
Aetna considers one intravitreal implant of Encelto (revakinagene taroretcel-lwey) per affected eye medically necessary for adults with idiopathic macular telangiectasia type 2 (MacTel) when the listed criteria are met, and considers all other indications experimental, investigational or unproven. The policy covers commercial medical plans, requires precertification in applicable plan designs, and requires that the drug be prescribed by or in consultation with an ophthalmologist. Members with intraretinal or subretinal neovascularization, anti-VEGF therapy within the past 3 months, glaucoma, uveitis, or current chemotherapy are listed as not eligible for the implant.
Aetna · Effective Jul 16, 2025Medium impact
Revakinagene Taroretcel-lwey (Encelto) (CPB 1079, reviewed 2026-07-17)
Aetna considers one intravitreal implant of revakinagene taroretcel-lwey (Encelto) medically necessary per affected eye for adults with idiopathic macular telangiectasia type 2 (MacTel) when all the listed criteria are met, and considers all other indications experimental, investigational or unproven. Eligibility requires fluorescein leakage in at least one eye with one of the listed features, a photoreceptor inner segment/outer segment break in the ellipsoid zone of 0.16 mm2 to 2.00 mm2 on spectral domain OCT, and best corrected visual acuity of 54 letters or better (20/80 or better) on the ETDRS chart. Exclusions include neovascular MacTel, prior intravitreal anti-VEGF therapy in the affected eye or in the non-affected eye within the past 3 months, glaucoma, uveitis, and inability to temporarily discontinue antithrombotic therapy. The implant must be prescribed by or in consultation with an ophthalmologist, and it requires precertification.
Aetna · Identified Nov 1, 2026Medium impact
Fluocinolone Acetonide Intra-vitreal Implant (Retisert, Yutiq and Iluvien) (CPB 0719, reviewed 2026-10-26)
Aetna's Clinical Policy Bulletin 0719 on fluocinolone acetonide intravitreal implants (Retisert, Yutiq and Iluvien) was last reviewed 10/26/2026. Aetna considers Retisert and Yutiq medically necessary for chronic non-infectious uveitis affecting the posterior segment in persons who do not respond to or are intolerant to conventional treatment, and considers Iluvien medically necessary for diabetic macular edema in persons previously treated with a course of corticosteroids who did not have a clinically significant rise in intraocular pressure. Retisert and Yutiq are contraindicated and considered not medically necessary for members with active ocular or periocular infections, and Iluvien is not considered medically necessary for members with active ocular or periocular infections or glaucoma with a cup to disc ratio greater than 0.8.

Watch E11.3211

Get one email when a payer policy names E11.3211, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code E11.3211?

There are 3 tracked policy changes affecting code E11.3211, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E11.3211?

Payers that have issued tracked updates for code E11.3211 include: Aetna.

How do I get notified when code E11.3211 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E11.3211. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E11.3211?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Revakinagene Taroretcel-lwey (Encelto) (CPB 1079, reviewed 2026-10-05)

Revakinagene Taroretcel-lwey (Encelto) (CPB 1079, reviewed 2026-07-17)

Fluocinolone Acetonide Intra-vitreal Implant (Retisert, Yutiq and Iluvien) (CPB 0719, reviewed 2026-10-26)

What insurance policy changes affect code E11.3211?

Which payers have updated policy for code E11.3211?

How do I get notified when code E11.3211 policy changes?

Why do payers change policies for code E11.3211?